SLAMF7 and Miyoshi myopathy: The mechanism of action of elotuzumab in MM patients involves the activation of natural killer (NK) cells through both CD16-mediated antibody dependent cellular cytotoxicity and direct co-stimulation via engagement with SLAMF7 as well as promoting antibody-dependent cellular phagocytosis by macrophages7,8,33.